<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325348</url>
  </required_header>
  <id_info>
    <org_study_id>IRB/2017/306/SIMS</org_study_id>
    <nct_id>NCT03325348</nct_id>
  </id_info>
  <brief_title>Oral Nifedipine Versus IV Labetalol in Severe Pre Eclampsia</brief_title>
  <official_title>Oral Nifedipine Versus IV Labetalol in Treatment of Severe Pre Eclampsia in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Services Institute of Medical Sciences, Pakistan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Services Institute of Medical Sciences, Pakistan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: To determine the efficacy of nifedipine and labetalol in terms of control of BP in
      pre eclamptic pregnant patients

      Design: Randomised control trial

      SETTING: Department Obstetrics &amp; gynaecology, Services Hospital, Services Institute of
      Medical Sciences. Lahore

      POPULATION: Pregnant patients with BP 160/110 or symptoms of severe preeclampsia

      METHODS: Patients are randomised to receive nifedipine (10 mg tablet, orally, up to five
      doses) and intravenous placebo saline injection or intravenous labetalol injection (in an
      escalating dose regimen of 20, 40, 80, 80 and 80 mg) and a placebo tablet every 15 minutes
      until the target blood pressure of ≤140/90mmHg is achieved. Crossover treatment is given if
      the initial treatment regimen is unsuccessful
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational hypertension is associated with increased risk of maternal morbidity and
      mortality. Parenteral therapy needs more resources, more monitoring and supervision. Oral
      therapy is cheap, easily available, easy to administer especially in resource constrained
      settings

      OBJECTIVE: To determine the efficacy of nifedipine and labetalol in terms of control of BP in
      pre eclamptic pregnant patients

      Design: Randomised control trial SETTING: Department Obstetrics &amp; gynaecology, Services
      Hospital, Services Institute of Medical Sciences.Lahore POPULATION: Pregnant patients with BP
      160/110 mm Hg or symptoms of severe preeclampsia

      METHODS: Patients are randomised to receive nifedipine (10 mg tablet, orally, up to five
      doses) and intravenous placebo saline injection or intravenous labetalol injection (in an
      escalating dose regimen of 20, 40, 80, 80 and 80 mg) and a placebo tablet every 15 minutes
      until the target blood pressure of ≤140/90mmHg is achieved. Crossover treatment is given if
      the initial treatment regimen is unsuccessful
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Anticipated">January 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time taken for Blood Pressure control</measure>
    <time_frame>60 minutes</time_frame>
    <description>Time taken to control Blood pressure will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal distress</measure>
    <time_frame>Labour</time_frame>
    <description>Fetal distress will be measured by abnormalities of fetal heart rate of fetus or passage of meconium.
of Meconium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Intensive Care Unit admission,</measure>
    <time_frame>From Birth till 7 days</time_frame>
    <description>If neonate needs Neonatal Intensive Care Unit admission for more than 12 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perinatal death</measure>
    <time_frame>From birth to 7 days</time_frame>
    <description>If death of baby occurs in utero or within 7 days of delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Severe Pre-Eclampsia, Antepartum</condition>
  <arm_group>
    <arm_group_label>Oral Nifedipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nifedipine 10mg oral tablet &amp; 1ml 0.9%N/Saline will be given every 15 minutes up till one hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Labetalol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV labetalol 20 mg and mint tablet will be given every 15 minutes up till one hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine 10 mg</intervention_name>
    <description>Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour</description>
    <arm_group_label>Oral Nifedipine</arm_group_label>
    <other_name>Cap nefidil 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <description>IV labetalol 20 mg &amp; mint tablet will be given to patients every 15 min until one hour</description>
    <arm_group_label>IV Labetalol</arm_group_label>
    <other_name>Labetalol Hydrochloride injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age 24 to 41 weeks

          -  BP &gt; 160/110 mm Hg with proteinuria

          -  Patients with S/S of imminent eclampsia as headache, visual disturbance.

        Exclusion Criteria:

          -  Gestational age &lt; 24 wks

          -  Non proteinuric chronic hypertension

          -  Eclampsia

          -  Cardiac patients, asthma, severe renal disease, allergy to Nifedipine or Labetalol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tayyiba Wasim, FCPS</last_name>
    <phone>+923008400197</phone>
    <email>tayyibawasim@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natasha Usman</last_name>
    <phone>+923008480027</phone>
    <email>natashausman5@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Services Institute of Medical Sciences</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TAYYIBA WASIM, FCPS</last_name>
      <phone>+923008400197</phone>
      <email>tayyibawasim@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Natasha Usman, FCPS</last_name>
      <email>natashausman5@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Services Institute of Medical Sciences, Pakistan</investigator_affiliation>
    <investigator_full_name>Tayyiba Wasim</investigator_full_name>
    <investigator_title>professor obs Gynecology</investigator_title>
  </responsible_party>
  <keyword>Severe Pre eclampsia</keyword>
  <keyword>Nifidepine</keyword>
  <keyword>Labetalol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Obstetric Labor Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Labetalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

